SGP Pengajuan SEC - Schering Plough Corp- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	4YV9Y5M8S0BRK1RP0397
CIK	310158

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Schering Plough Corp

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

September 4, 2025	424B5	$6,000,000,000 Merck & Co., Inc., Rahway, N.J., USA $500,000,000 Floating Rate Notes due 2027 $750,000,000 3.850% Notes due 2027 $750,000,000 4.150% Notes due 2030 $1,000,000,000 4.550% Notes due 2032 $1,750,000,000 4.950% Notes due 2035 $1,250,000,0 Filed pursuant to Rule 424(b)(5) Registration No. 333-278066 Prospectus Supplement (To Prospectus dated May 14, 2024) $6,000,000,000 Merck & Co., Inc., Rahway, N.J., USA $500,000,000 Floating Rate Notes due 2027 $750,000,000 3.850% Notes due 2027 $750,000,000 4.150% Notes due 2030 $1,000,000,000 4.550% Notes due 2032 $1,750,000,000 4.950% Notes due 2035 $1,250,000,000 5.700% Notes due 2055 We are
September 4, 2025	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 Merck & Co., Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial E
September 3, 2025	FWP	Pricing Term Sheet Merck & Co., Inc. September 2, 2025 Floating Rate Notes due 2027 3.850% Notes due 2027 4.150% Notes due 2030 4.550% Notes due 2032 4.950% Notes due 2035 5.700% Notes due 2055 Issuer Free Writing Prospectus Filed under Rule 433 Registration Statement No. 333-278066 Pricing Term Sheet Merck & Co., Inc. September 2, 2025 Floating Rate Notes due 2027 3.850% Notes due 2027 4.150% Notes due 2030 4.550% Notes due 2032 4.950% Notes due 2035 5.700% Notes due 2055 The 3.850% Notes due 2027, 4.150% Notes due 2030, 4.550% Notes due 2032, 4.950% Notes due 2035 and 5.700% Notes due
September 2, 2025	424B5	The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy thes Filed pursuant to Rule 424(b)(5) Registration No. 333-278066 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is unlawful or not permitted. Su
August 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exact nam
July 29, 2025	EX-99.1	- 1 - Exhibit 99.1 - 1 - News Release Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results - Total Worldwide Sales Were $15.8 Billion, a Decrease of 2% From Second Quarter 2024 Both Nominally and Excluding the Impact of Foreign Exchange o KEYTRUDA Sales Were $8.0 Billion, Growth of 9% Both Nominally and Excluding the Impact of Foreign Exchange o WINREVAIR Sales Were $336
July 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2025 (July 25, 2025) Merc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2025 (July 25, 2025) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File
July 29, 2025	EX-99.2	MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC., RAHWAY, N.J., USA CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2025 2024 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD Sales $ 15,529 $ 15,806 $ 31,335 $ 15,775 $ 16,112 $ 31,887 $ 16,657 $ 15,624 $ 64,168 -2 % -2 % Costs, Expenses and Other Cost of sales 3,419 3,557 6,976 3,540 3,7
June 27, 2025	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1
June 27, 2025	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1
June 27, 2025	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 11-K 1 a11-kmerckussavingsplanye.htm 11-K MERCK US SAVINGS PLAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ende
May 30, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report Merck & Co., Inc. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report Merck & Co., Inc. (Exact Name of Registrant as Specified in Its Charter) New Jersey 1-6571 (State or other jurisdiction of incorporation or organization) (Commission File Number) 126 East Lincoln Avenue, Rahway, NJ 07065 (Address of principal executive offices) (Zip Code) Jennifer Zachary
May 30, 2025	EX-1.01	Exhibit 1.01 – Conflict Minerals Report for the reporting period January 1, 2024 to December 31, 2024. Exhibit 1.01 CONFLICT MINERALS REPORT FOR CALENDAR YEAR 2024 Part I: Introduction This document constitutes Merck & Co., Inc.’s Conflict Minerals Report (the “Report” or “CMR”) for the year ended December 31, 2024. We have prepared this Report and are issuing it in accordance with the requirements of Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and in connection with Merck & C
May 29, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 29, 2025 (May 27, 2025) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File N
May 7, 2025	PX14A6G	United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Merck & Co., Inc. Name of persons relying on exemption: National Legal and Policy Center Address of persons relying on exemption: 107 Park Washington Court, Falls Church, VA 22046 Written materials are submitted pursuant to Rule 14a-6(g) (1) promulg
May 2, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exact na
April 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2025 (April 24, 2025) Me UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2025 (April 24, 2025) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission Fi
April 24, 2025	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2025 2024 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q Sales $ 15,529 $ 15,775 $ 16,112 $ 16,657 $ 15,624 $ 64,168 -2 % Costs, Expenses and Other Cost of sales 3,419 3,540 3,745 4,080 3,828 15,193 -3 % Selling, general and administrative 2,552 2,483 2,739 2,731 2,864
April 24, 2025	PX14A6G	Notice of Exempt Solicitation Pursuant to Rule 14a-103 Notice of Exempt Solicitation Pursuant to Rule 14a-103 Name of Registrant: Merck & Co.
April 24, 2025	EX-99.1	Merck Announces First-Quarter 2025 Financial Results Exhibit 99.1 News Release Merck Announces First-Quarter 2025 Financial Results - Total Worldwide Sales Were $15.5 Billion, a Decrease of 2% From First Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 1% o KEYTRUDA Sales Grew 4% to $7.2 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 6% o WINREVAIR Sales Were $280 Million o Animal Health Sales Grew 5% to $1.6 Billion
April 16, 2025	CORRESP	126 East Lincoln Avenue P.O. Box 2000 Rahway, NJ 07065 T: 908-740-4000 E: [email protected] merck.com April 16, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N 126 East Lincoln Avenue P.O. Box 2000 Rahway, NJ 07065 T: 908-740-4000 E: [email protected] merck.com April 16, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 RE: Merck & Co., Inc. Form 10-K for the Fiscal Year Ended December 31, 2024 File No. 1-06571 Ladies and Gentlemen: Merck &
April 14, 2025	PX14A6G	This is not a solicitation of authority to vote your proxy. Please DO NOT send us your proxy card as it will not be accepted Notice of Exempt Solicitation NAME OF REGISTRANT: Merck & Co., Inc NAME OF PERSON RELYING ON EXEMPTION: Mercy Investment Services ADDRESS OF PERSON RELYING ON EXEMPTION: 2039 N Geyer Rd, Frontenac, MO 63131 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. The soliciting person does not beneficially own more than $5 million of the c
April 9, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2
April 9, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit
February 25, 2025	EX-10.31	Form of restricted stock unit terms for 2024 annual grants under the Merck & Co., Inc. 2019 Incentive Stock Plan GLOBAL TERMS AND CONDITIONS 2024 RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO.
February 25, 2025	EX-10.33	Form of stock option terms for 2024 annual non-qualified option grants under the Merck & Co., Inc. 2019 Incentive Stock Plan GLOBAL TERMS AND CONDITIONS 2024 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO.
February 25, 2025	EX-19	Insider Trading Policy Corporate Policy 11.0: Insider Trading Exhibit 19 What You Need to Know As employees of Merck & Co., Inc., Rahway, NJ, USA known as MSD outside the United States and Canada (our Company), we, our family members and related persons do not trade in our Company securities – or tip others to do so – based on material, non-public (or “inside”) information. We recognize that insider trading undermines i
February 25, 2025	EX-10.1	Merck & Co., Inc. Executive Incentive Plan (as amended and restated effective January 1, 2025) I.INTRODUCTION The Plan is designed to provide for awards to selected salaried employees in managerial or other important positions, who, individually or as members of a group, contribute in a substantial degree to the success of the Company, and who are in a position to have a direct and significant impact on the growth and success of the Company, thus affording to them a means of participating i
February 25, 2025	EX-10.32	2024 Performance Share Unit terms for grants under the Merck & Co., Inc. 2019 Incentive Stock Plan GLOBAL TERMS AND CONDITIONS 2024 PERFORMANCE SHARE UNIT GRANTS UNDER THE MERCK & CO.
February 25, 2025	EX-10.35	Offer Letter between Merck & Co., Inc. and Betty Larson, dated January 16, 2024 Confidential January 16, 2024 Betty Larson 159 Abingdon Avenue Kenilworth, IL 60043 Dear Betty, It is my pleasure to offer you a position with Merck Sharp & Dohme LLC (“MSD” or the “Company”), a wholly-owned subsidiary of Merck & Co.
February 25, 2025	EX-10.36	Restricted stock unit terms for April 30, 2024 grant to Betty Larson under the Merck & Co., Inc. 2019 Incentive Stock Plan GLOBAL TERMS AND CONDITIONS 2024 SIGN-ON EQUITY GRANT OF RESTRICTED STOCK UNIT GRANTS FOR BETTY LARSON UNDER THE MERCK & CO.
February 25, 2025	EX-10.13	Merck & Co., Inc. U.S. Separation Benefits Plan (amended and restated as of January 1, 2019) as further amended by Amendments 2019-1 (as of December 19, 2019), 2020-1 (as of February 25, 2020), 2020-2 (as of December 10, 2020), 2021-1 (as of March 31, 2021), 2021-2 (as of December 16, 2021), 2022-1 (as of December 14, 2022), 2022-2 (as of December 13, 2021), 2023-1 (as of December 15, 2023) and 2024-1 (as of October 22, 2024) MERCK & CO. INC. U.S. SEPARATION BENEFITS PLAN Amended and Restated as of January 1, 2019 MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN SECTION 1 PREAMBLE Merck Sharp & Dohme Corp. established the MSD Separation Benefits Plan (the "MSD Plan"), as amended from time to time, to provide benefits to eligible non-union employees whose employment with Merck Sharp & Dohme Corp. or a participating whol
February 25, 2025	EX-24.2	Certified Resolution of Board of Directors Exhibit 24.2 I, Kelly Grez, Corporate Secretary of Merck & Co., Inc. (the “Company”), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 25, 2025 in accordance with the provisions of the By-Laws of the Compan
February 25, 2025	EX-4.11	the Registrant Exhibit 4.11 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 25, 2025, Merck & Co., Inc. had eight classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (i) Common Stock, (ii), 1.875% Notes due 2026, (iii) 3.250% Notes due 2032, (iv) 2.500% Notes due 2034, (v) 1.375% N
February 25, 2025	EX-24.1	Power of Attorney Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned does hereby appoint JENNIFER ZACHARY as his/her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2024 under th
February 25, 2025	EX-10.34	Restricted stock unit terms for April 30, 2024 grant to Richard DeLuca under the Merck & Co., Inc. 2019 Incentive Stock Plan GLOBAL TERMS AND CONDITIONS 2024 RETENTION RESTRICTED STOCK UNIT GRANT FOR RICHARD DELUCA UNDER THE MERCK & CO.
February 25, 2025	10-K	As filed with the Securities and Exchange Commission on February 25, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For th As filed with the Securities and Exchange Commission on February 25, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
February 25, 2025	EX-21	Subsidiaries of Merck & Co., Inc. Exhibit 21 - MERCK & CO., INC. SUBSIDIARIES changes as 12/31/2024 The following is a list of subsidiaries of the Company, doing business under the name stated. Name Country or State of Incorporation 7728026 Canada Inc. Canada Abceutics, Inc. Delaware Abmaxis Inc. Delaware Acceleron Pharma Inc. Delaware Afferent Pharmaceuticals, Inc. Delaware Agrident GmbH Germany Allflex Argentina S.A. Argentina A
February 4, 2025	EX-99.1	Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results Exhibit 99.1 News Release Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results - Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 9% - Fourth-Quarter GAAP EPS Was $1.48; Non-GAAP EPS Was $1.72; GAAP and Non-GAAP EPS Include a Charge of $0.23 per Share Related to Certain Business Develo
February 4, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2025 (February 4, 2025) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commissio
February 4, 2025	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2024 2023 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year Sales $ 15,775 $ 16,112 $ 16,657 $ 15,624 $ 64,168 $ 14,487 $ 15,035 $ 15,962 $ 14,630 $ 60,115 7 % 7 % Costs, Expenses and Other Cost of sales 3,540 3,745 4,080 3,828 15,193 3,926
December 23, 2024	EX-99.1	Joint Filing Agreement Pursuant to Rule 13d-1 Exhibit 99.1 Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”) by and among the parties listed below, each referenced to herein as a “Joint Filer.” The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereu
November 22, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 22, 2024 (November 19, 2024) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commiss
November 22, 2024	EX-99.1	Surendralal Karsanbhai Elected to Merck Board of Directors Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Surendralal Karsanbhai Elected to Merck Board of Directors RAHWAY, N.J., Nov. 22, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that Surendralal L. “Lal” Karsanbhai, president and chief executive officer, Emerson Electric Co. (NYSE: EMR), will join Merck’s board of directors effective January 1, 2025.
November 22, 2024	EX-3.1	By-Laws of Merck & Co., Inc. (effective November 19. 2024) – Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on November 22, 2024 (No. 1-6571) Exhibit 3.1 By-Laws OF MERCK & CO., INC. Effective as of November 19, 2024 By-Laws OF Merck & Co., Inc. A R T I C L E I. SHAREHOLDERS. SECTION 1. Annual Meeting. A meeting of the shareholders of Merck & Co., Inc. (hereinafter referred to as the “Company”) shall be held at such places as may from time to time be designated by the Board of Directors and stated in the notice of the meeting for the pu
November 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exac
November 6, 2024	SC 13G/A	EVAX / Evaxion Biotech A/S - Depositary Receipt (Common Stock) / Merck & Co., Inc. Passive Investment SC 13G/A 1 ff408710013ga1-evaxion.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Evaxion Biotech A/S (Name of Issuer) Ordinary Shares, DKK 1 nominal value per share (Title of Class of Securities) 29970R204** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement)
November 4, 2024	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on November 15, 2024, pursuant to the provisions of Rule 12d2-2 (a).
October 31, 2024	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2024 2023 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD Sales $ 15,775 $ 16,112 $ 16,657 $ 48,544 $ 14,487 $ 15,035 $ 15,962 $ 45,485 $ 14,630 $ 60,115 4 % 7 % Costs, Expenses and Other Cost of sales 3,540 3,745 4,080 11,365 3,926 4,02
October 31, 2024	EX-99.1	Merck Announces Third-Quarter 2024 Financial Results Exhibit 99.1 News Release Merck Announces Third-Quarter 2024 Financial Results - Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 7% o KEYTRUDA Sales Grew 17% to $7.4 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% o WINREVAIR Sales Were $149 Million; U.S. Launch of WINREVAIR Gaining Momentum
October 31, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2024 (October 31, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2024 (October 31, 2024) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commissio
August 5, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exact nam
July 30, 2024	EX-99.1	Merck Announces Second-Quarter 2024 Financial Results Exhibit 99.1 News Release Merck Announces Second-Quarter 2024 Financial Results - Total Worldwide Sales Were $16.1 Billion, an Increase of 7% From Second Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 11% - KEYTRUDA Sales Grew 16% to $7.3 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% - GAAP EPS Was $2.14; Non-GAAP EPS Was $2.28 - Successful Initial Launch of
July 30, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2024 (July 30, 2024) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File
July 30, 2024	EX-99.2	MERCK & CO., INC. THREE AND SIX MONTHS ENDED JUNE 30, 2023 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 2b Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2024 2023 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD Sales $ 15,775 $ 16,112 $ 31,887 $ 14,487 $ 15,035 $ 29,522 $ 15,962 $ 14,630 $ 60,115 7 % 8 % Costs, Expenses and Other Cost of sales 3,540 3,745 7,285 3,926 4,024 7,951 4,264 3,
June 25, 2024	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1
June 25, 2024	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1
June 25, 2024	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1
May 30, 2024	EX-4.5	3.750% Notes due 2054 Officer’s Certificate of MSD Netherlands dated May 30, 2024, including form of the 2054 Notes (incorporated by reference to Exhibit 4.5 to Merck & Co., Inc.’s Current Report on Form 8-K filed with the SEC on May 30, 2024). Exhibit 4.5 3.750% NOTES DUE 2054 MSD NETHERLANDS CAPITAL B.V. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the board of directors of MSD Netherlands Capital B.V., (the “Company”) duly adopted and dated May 13, 2024, which authorized the Company to issue and sell its debt securities and empowered each director of the Company (the “Officer”) to approve the
May 30, 2024	EX-4.1	herlands Capital B.V., Merck & Co., Inc. and U.S. Bank Trust National Association Exhibit 4.1 MSD NETHERLANDS CAPITAL B.V. AND MERCK & CO., INC., as Parent Guarantor TO U.S. BANK TRUST NATIONAL ASSOCIATION, as Trustee Indenture Dated as of May 30, 2024 MSD NETHERLANDS CAPITAL B.V. MERCK & CO., INC. Certain Sections of this Indenture relating to Sections 310 through 318, inclusive, of the Trust Indenture Act of 1939 Trust Indenture Act Sections Indenture Sections § 310(a)(1) 609
May 30, 2024	EX-4.3	3.500% Notes due 2037 Officer’s Certificate of MSD Netherlands dated May 30, 2024, including form of the 2037 Notes (incorporated by reference to Exhibit 4.3 to Merck & Co., Inc.’s Current Report on Form 8-K filed with the SEC on May 30, 2024). Exhibit 4.3 3.500% NOTES DUE 2037 MSD NETHERLANDS CAPITAL B.V. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the board of directors of MSD Netherlands Capital B.V., (the “Company”) duly adopted and dated May 13, 2024, which authorized the Company to issue and sell its debt securities and empowered each director of the Company (the “Officer”) to approve the
May 30, 2024	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Merck & Co., Inc. (Exact name of registrant as UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation or organization) 22-1918501 (I.R.S Employer Identification No.) 126
May 30, 2024	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commission File Numb
May 30, 2024	EX-4.4	3.700% Notes due 2044 Officer’s Certificate of MSD Netherlands dated May 30, 2024, including form of the 2044 Notes (incorporated by reference to Exhibit 4.4 to Merck & Co., Inc.’s Current Report on Form 8-K filed with the SEC on May 30, 2024). Exhibit 4.4 3.700% NOTES DUE 2044 MSD NETHERLANDS CAPITAL B.V. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the board of directors of MSD Netherlands Capital B.V., (the “Company”) duly adopted and dated May 13, 2024, which authorized the Company to issue and sell its debt securities and empowered each director of the Company (the “Officer”) to approve the
May 30, 2024	EX-4.2	3.250% Notes due 2032 Officer’s Certificate of MSD Netherlands dated May 30, 2024, including form of the 2032 Notes (incorporated by reference to Exhibit 4.2 to Merck & Co., Inc.’s Current Report on Form 8-K filed with the SEC on May 30, 2024). Exhibit 4.2 3.250% NOTES DUE 2032 MSD NETHERLANDS CAPITAL B.V. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the board of directors of MSD Netherlands Capital B.V., (the “Company”) duly adopted and dated May 13, 2024, which authorized the Company to issue and sell its debt securities and empowered each director of the Company (the “Officer”) to approve the
May 28, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report Merck & Co., Inc. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report Merck & Co., Inc. (Exact Name of Registrant as Specified in Its Charter) New Jersey 1-6571 (State or other jurisdiction of incorporation or organization) (Commission File Number) 126 East Lincoln Avenue, Rahway, NJ 07065 (Address of principal executive offices) (Zip Code) Jennifer Zachary
May 28, 2024	EX-1.01	Exhibit 1.01 – Conflict Minerals Report for the reporting period January 1, 2023 to December 31, 2023. Exhibit 1.01 CONFLICT MINERALS REPORT FOR CALENDAR YEAR 2023 Part I: Introduction This document constitutes Merck & Co., Inc.’s Conflict Minerals Report (the “Report” or “CMR”) for the year ended December 31, 2023. We have prepared this Report and are issuing it in accordance with the requirements of Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and in connection with Merck & C
May 20, 2024	424B5	Filed pursuant to Rule 424(b)(5) Filed pursuant to Rule 424(b)(5) Registration No. 333-278066 333-278066-01 Prospectus Supplement (To Prospectus dated May 14, 2024) €3,400,000,000 MSD Netherlands Capital B.V. (incorporated as a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) under the laws of the Netherlands with its official seat (statutaire zetel) in Haarlem, the Netherlands) Guaran
May 20, 2024	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Merck & Co., Inc. MSD Netherlands Capital B.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculati Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Merck & Co., Inc. MSD Netherlands Capital B.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate
May 16, 2024	FWP	Pricing Term Sheet MSD Netherlands Capital B.V. (the “Issuer”) May 16, 2024 3.250% Notes due 2032 3.500% Notes due 2037 3.700% Notes due 2044 3.750% Notes due 2054 Issuer Free Writing Prospectus Filed under Rule 433 Registration Statement No. 333-278066 333-278066-01 Pricing Term Sheet MSD Netherlands Capital B.V. (the “Issuer”) May 16, 2024 3.250% Notes due 2032 3.500% Notes due 2037 3.700% Notes due 2044 3.750% Notes due 2054 Issuer: MSD Netherlands Capital B.V. Guarantor: Merck & Co., Inc., Rahway, N.J., USA Expected Ratings of the Notes:* A1 (positive) M
May 15, 2024	EX-5.(C)	Consent of Loyens & Loeff N.V. (contained in Exhibit 5(c) to this registration statement). Exhibit 5(c) POSTAL ADDRESS P.O. Box 71170 1008 BD AMSTERDAM OFFICE ADDRESS Parnassusweg 300 1081 LC AMSTERDAM The Netherlands INTERNET www.loyensloeff.com To: MSD Netherlands Capital B.V. Waarderweg 39 2031 BN Haarlem The Netherlands RE Dutch law legal opinion – MSD Netherlands Capital B.V. – SEC Registration REFERENCE 53996680 DATE 14 May 2024 1 INTRODUCTION We have acted as special counsel on c
May 15, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Merck & Co., Inc. MSD Netherlands Capital B.V. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amo
May 15, 2024	POSASR	As filed with the Securities and Exchange Commission on May 14, 2024 As filed with the Securities and Exchange Commission on May 14, 2024 Registration No.
May 15, 2024	424B5	Filed pursuant to Rule 424(b)(5) Filed pursuant to Rule 424(b)(5) Registration No. 333-278066 333-278066-01 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is unlawful or not
May 15, 2024	EX-1.(B)	Form of Underwriting Agreement for MSD Netherlands Capital B.V. debt securities. Exhibit 1(b) MSD Netherlands Capital B.V. Form of Debt Underwriting Agreement , 20 [Names and addresses of Underwriters] Ladies and Gentlemen: MSD Netherlands Capital B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated and existing under the laws of The Netherlands (the “Issuer”) registered with the Dutch Trade Register of the Dutch Ch
May 15, 2024	EX-25.(B)	Form T-1 Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of U.S. Bank Trust National Association with respect to the MSD Netherlands Indenture. Exhibit 25(b) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ☐ U.S. BANK TRUST NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 41-1973763 I.R.S. Employer
May 15, 2024	EX-4.(B)	Form of Indenture among MSD Netherlands Capital B.V., Merck & Co., Inc. and U.S. Bank Trust National Association, as Trustee (the “MSD Netherlands Indenture”). Exhibit 4(b) MSD NETHERLANDS CAPITAL B.V. AND MERCK & CO., INC., as Parent Guarantor TO U.S. BANK TRUST NATIONAL ASSOCIATION, as Trustee Indenture Dated as of [ ], 20[ ] MSD NETHERLANDS CAPITAL B.V. MERCK & CO., INC. Certain Sections of this Indenture relating to Sections 310 through 318, inclusive, of the Trust Indenture Act of 1939 Trust Indenture Act Sections Indenture Sections § 310(a)(1) 609
May 15, 2024	EX-5.(B)	Consent of Jennifer Zachary, Esq., Executive Vice President and General Counsel of Merck & Co., Inc. (contained in Exhibit 5(b) to this registration statement). Exhibit 5(b) [Letterhead of Merck & Co., Inc.] May 14, 2024 Merck & Co., Inc. 126 East Lincoln Avenue Rahway, NJ 07065 MSD Netherlands Capital B.V. Waarderweg 39 2031 BN Haarlem, the Netherlands Re: Merck & Co., Inc. and MSD Netherlands Capital B.V. – Debt Securities and Guarantees Ladies and Gentlemen: I am the Executive Vice President and General Counsel of Merck & Co., Inc., a New Jersey corpor
May 15, 2024	EX-23.(A)	Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm for Merck & Co., Inc. Exhibit 23(a) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 of Merck & Co.
May 3, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exact na
April 25, 2024	EX-99.1	Merck Announces First-Quarter 2024 Financial Results Exhibit 99.1 News Release Merck Announces First-Quarter 2024 Financial Results - Sales Reflect Continued Strong Growth in Oncology and Vaccines - Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 12% o KEYTRUDA Sales Grew 20% to $6.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 24% o GARDASIL/G
April 25, 2024	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2024 2023 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q Sales $ 15,775 $ 14,487 $ 15,035 $ 15,962 $ 14,630 $ 60,115 9 % Costs, Expenses and Other Cost of sales 3,540 3,926 4,024 4,264 3,911 16,126 -10 % Selling, general and administrative 2,483 2,479 2,702 2,519 2,
April 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2024 (April 25, 2024) Me UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2024 (April 25, 2024) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission Fi
April 11, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2
April 11, 2024	10-K/A	As filed with the Securities and Exchange Commission on April 11, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K/A (Amendment No. 1) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange A As filed with the Securities and Exchange Commission on April 11, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
April 11, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy
April 1, 2024	PX14A6G	United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Merck & Co., Inc. Name of persons relying on exemption: Inspire Investing, LLC Address of persons relying on exemption: 3597 E Monarch Sky Ln, Suite 330, Meridian, ID 83646 As over 100 investors and financial professionals, serving thousands of clie
March 28, 2024	PX14A6G	Vote Yes: Report on Respecting Workforce Civil Liberties NOTICE OF EXEMPT SOLICITATION SUBMITTED BY NON-MANAGEMENT U.S. Securities and Exchange Commission Washington, DC 20549 Notice of Exempt Solicitation under Rule 14a-103 Name of Registrant: Merck & Co., Inc. Name of person relying on exemption: Bowyer Research Address of person relying on exemption: P.O. Box 120, McKeesport, PA 15135 Vote Yes: Report on Respecting Workforce Civil Liberties Bowyer Re
March 19, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Merck & Co., Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of
March 19, 2024	EX-1	Form of Underwriting Agreement. Exhibit 1 MERCK & CO., INC. Form of Debt Underwriting Agreement , 20 [Names and addresses of Representatives] As Representatives of the several Underwriters named in Schedule I hereto Ladies and Gentlemen: Merck & Co., Inc., a New Jersey corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the firms named in Schedule I hereto (the “Unde
March 19, 2024	EX-23.A	Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm for the Registrant. EX-23.A Exhibit 23(a) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 of Merck & Co., Inc. of our report dated February 26, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Merck & Co., Inc.’s Annual Report on Form 10-
March 19, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Merck & Co., Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of
March 19, 2024	EX-25	Form T-1 Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of U.S. Bank Trust National Association. Exhibit 25 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 41-1973763 I.R.S. Employer Ide
March 19, 2024	S-3ASR	As filed with the Securities and Exchange Commission on March 19, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 19, 2024 Registration No.
March 19, 2024	S-3ASR	As filed with the Securities and Exchange Commission on March 19, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 19, 2024 Registration No.
March 19, 2024	EX-23.A	Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm for the Registrant. EX-23.A Exhibit 23(a) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 of Merck & Co., Inc. of our report dated February 26, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Merck & Co., Inc.’s Annual Report on Form 10-
February 26, 2024	EX-10.13	Merck & Co., Inc. U.S. Separation Benefits Plan (amended and restated as of January 1, 2019) as further amended by Amendments 2019-1 (as of December 19, 2019), 2020-1 (as of February 25, 2020), 2020-2 (as of December 10, 2020), 2021-1 (as of March 31, 2021), 2021-2 (as of December 16, 2021), 2022-1 (as of December 14, 2022) and 2022-2 (as of December 13, 2021) - Exhibit 10.13 MERCK & CO. INC. U.S. SEPARATION BENEFITS PLAN Amended and Restated as of January 1, 2019 MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN SECTION 1 PREAMBLE Merck Sharp & Dohme Corp. established the MSD Separation Benefits Plan (the "MSD Plan"), as amended from time to time, to provide benefits to eligible non-union employees whose employment with Merck Sharp & Dohme Corp. or a part
February 26, 2024	EX-24.2	Certified Resolution of Board of Directors Exhibit 24.2 I, Kelly Grez, Corporate Secretary of Merck & Co., Inc. (the “Company”), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 24, 2023 in accordance with the provisions of the By-Laws of the Compan
February 26, 2024	EX-24.1	Power of Attorney Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned does hereby appoint JENNIFER ZACHARY as his/her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2023 under th
February 26, 2024	EX-10.24	Terms for Restricted Stock Unit Grants under the Merck & Co., Inc. 2019 Incentive Stock Plan - Exhibit 10.24 TERMS FOR 2021 RETENTION RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO., 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document. Different terms may apply to any prior or future RSU Awards. Grant Type: RSU Grant Date: May 4, 2021 Vesting Date Portion that Vests May 4, 2024 100% Eligibility: Eligibili
February 26, 2024	EX-10.30	Offer Letter between Merck & Co., Inc. and Chirfi Guindo, dated June 8, 2022—Incorporated by reference to Exhibit 10.30 to Merck & Co., Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2022 filed February 24, 2023 (No. 1-6571) Exhibit 10.30 June 8, 2022 Chirfi Guindo Dear Chirfi, It is my pleasure to offer you a position with Merck Sharp & Dohme LLC (“MSD” or the “Company”), a wholly-owned subsidiary of Merck & Co., Inc. (“Merck”), as its Chief Marketing Officer (the “Position”) on the terms and conditions set forth in this offer letter (“letter” or “offer letter”). We see ourselves as a company inspired to invent, and
February 26, 2024	10-K	As filed with the Securities and Exchange Commission on February 26, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For th As filed with the Securities and Exchange Commission on February 26, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
February 26, 2024	EX-21	Subsidiaries of Merck & Co., Inc. Exhibit 21 - MERCK & CO., INC. SUBSIDIARIES changes as 12/31/2023 The following is a list of subsidiaries of the Company, doing business under the name stated. Name Country or State of Incorporation 7728026 Canada Inc. Canada Abmaxis Inc. Delaware Acceleron Pharma Inc. Delaware Afferent Pharmaceuticals, Inc. Delaware Agrident GmbH Germany Agro Verhen B.V. Netherlands Allflex Argentina S.A. Argenti
February 26, 2024	EX-10.25	Restricted stock unit terms for August 3, 2022 grant to Chirfi Guindo under the Merck & Co., Inc. 2019 Incentive Stock Plan - Exhibit 10.25 GLOBAL TERMS AND CONDITIONS 2022 RESTRICTED STOCK UNIT GRANT FOR CHIRFI GUINDO UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the Restricted Stock Unit (“RSU”) award specified in this document (“RSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country
February 26, 2024	EX-10.28	2022 Performance Share Unit terms for grant under the Merck & Co., Inc. 2019 Incentive Stock Plan — Incorporated by reference to Exhibit 10.28 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571) Exhibit 10.28 GLOBAL TERMS AND CONDITIONS 2022 PERFORMANCE SHARE UNIT GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the award of Performance Share Units (“PSUs”) specified in this document (“PSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Pla
February 26, 2024	EX-10.22	Form of restricted stock unit terms for 2020 annual grants under the Merck & Co., Inc. 2019 Incentive Stock Plan - Exhibit 10.22 TERMS FOR 2020 RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO., 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document. Different terms may apply to any prior or future RSU Awards. Grant Type: RSU - Annual Grant Date: May 1, 2020 Vesting Dates Portion that Vests May 1, 2021 First: 33.333% May 1, 2022
February 26, 2024	EX-97	Policy and Procedures for Recoupment of Incentive-Based Compensation Exhibit 97 Policy and Procedures for Recoupment of Incentive‐Based Compensation Policy The Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) has adopted this Incentive‐Based Compensation Recoupment Policy (the “Policy”) to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10D‐1 promulgated thereunder (“Rule 10D‐1”) and Paragraph 303A.
February 26, 2024	EX-10.8	Form of stock option terms for 2019 annual non-qualified option grants under the Merck & Co., Inc. 2010 Incentive Stock Plan - Exhibit 10.8 TERMS FOR 2019 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: NQSO – Annual Option Price: $77.62 Grant Date: May 3, 2019 Expiration Date: May 2, 2029 Vesting Date Portion tha
February 26, 2024	EX-10.27	Form of restricted stock unit terms for 2020 annual grants under the Merck & Co., Inc. 2019 Incentive Stock Plan — Exhibit 10.27 GLOBAL TERMS AND CONDITIONS 2023 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the stock option specified in this document pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Plan”). This stock option is subjec
February 26, 2024	EX-10.23	2021 Performance Share Unit terms for grants under the Merck & Co., Inc. 2019 Incentive Stock Plan — Exhibit 10.23 2021 PERFORMANCE SHARE UNIT AWARD TERMS UNDER THE MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, independent, p
February 26, 2024	EX-10.21	Form of stock option terms for 2020 annual non-qualified option grants under the Merck & Co., Inc. 2019 Incentive Stock Plan — Exhibit 10.21 TERMS FOR 2020 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: NQSO – Annual Option Price: $77.67 Grant Date: May 1, 2020 Expiration Date: April 31, 2030 Vesting Dates Portio
February 26, 2024	EX-10.26	Performance share unit terms for August 3, 2022 grant to Chirfi Guindo under the Merck & Co., Inc. 2019 Incentive Stock Plan - Exhibit 10.26 GLOBAL TERMS AND CONDITIONS 2022 SIGN-ON EQUITY GRANT OF PERFORMANCE SHARE UNITS FOR CHIRFI GUINDO UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the award of Performance Share Units (“PSUs”) specified in this document (“PSU Award” or “Sign-On Equity”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, i
February 26, 2024	EX-10.29	2023 Performance Share Unit terms for grant under the Merck & Co., Inc. 2019 Incentive Stock Plan — Incorporated by reference to Exhibit 10.29 to Merck & Co, Inc.’s Form 10-K Annual Report for the fiscal year ended December 31, 2023 filed February 26, 2024 (No. 1-6571) Exhibit 10.29 GLOBAL TERMS AND CONDITIONS 2023 PERFORMANCE SHARE UNIT GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the award of Performance Share Units (“PSUs”) specified in this document (“PSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Pla
February 26, 2024	EX-10.7	Form of stock option terms for 2017 annual non-qualified option grants under the Merck & Co., Inc. 2010 Incentive Stock Plan - Exhibit 10.7 TERMS FOR 2017 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: NQSO Option Price: $63.97 Grant Date: May 5, 2017 Expiration Date: May 4, 2027 Vesting Date Portion that Vests M
February 20, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 20, 2024 (February 15, 2024) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commiss
February 13, 2024	SC 13G/A	MRK / Merck & Co., Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0090-merckcoinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Merck & Co Inc Title of Class of Securities: Common Stock CUSIP Number: 58933Y105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule
February 1, 2024	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2023 2022 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year Sales $ 14,487 $ 15,035 $ 15,962 $ 14,630 $ 60,115 $ 15,901 $ 14,593 $ 14,959 $ 13,830 $ 59,283 6 % 1 % Costs, Expenses and Other Cost of sales 3,926 4,024 4,264 3,911 16,126 5,380
February 1, 2024	8-K	Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2024 (January 29, 2024) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commissio
February 1, 2024	EX-99.1	Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results Exhibit 99.1 News Release Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results - Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines - Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 13% - Fourth-Qua
January 23, 2024	EX-99.1	Joint Filing Agreement Pursuant to Rule 13d-1 Exhibit 99.1 Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”) by and among the parties listed below, each referenced to herein as a “Joint Filer.” The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereu
January 23, 2024	SC 13G	EVAX / Evaxion Biotech A/S - Depositary Receipt (Common Stock) / Merck & Co., Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Evaxion Biotech A/S (Name of Issuer) Ordinary Shares, DKK 1 nominal value per share (Title of Class of Securities) 29970R204** (CUSIP Number) December 21, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
November 28, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 28, 2023 (November 21, 2023) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commiss
November 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exac
October 26, 2023	EX-99.1	Merck Announces Third-Quarter 2023 Financial Results Exhibit 99.1 News Release Merck Announces Third-Quarter 2023 Financial Results - Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines - Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022; Excluding LAGEVRIO, Growth Was 6%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 8% o KEYTRUDA Sales Grew 17% to $6.3 Billion; Excluding the I
October 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 26, 2023 Merck & Co., Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 26, 2023 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1
October 26, 2023	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2023 2022 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD Sales $ 14,487 $ 15,035 $ 15,962 $ 45,485 $ 15,901 $ 14,593 $ 14,959 $ 45,453 $ 13,830 $ 59,283 7 % – Costs, Expenses and Other Cost of sales 3,926 4,024 4,264 12,214 5,380 4,216
August 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exact nam
August 1, 2023	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2023 2022 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD Sales $ 14,487 $ 15,035 $ 29,522 $ 15,901 $ 14,593 $ 30,494 $ 14,959 $ 13,830 $ 59,283 3 % -3 % Costs, Expenses and Other Cost of sales 3,926 4,024 7,951 5,380 4,216 9,596 3,934 3
August 1, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2023 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-191
August 1, 2023	EX-99.1	Merck Announces Second-Quarter 2023 Financial Results Exhibit 99.1 News Release Merck Announces Second-Quarter 2023 Financial Results - Sales Reflect Sustained Underlying Growth, Particularly in Oncology and Vaccines - Total Worldwide Sales Were $15.0 Billion, an Increase of 3% From Second Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 14% ○ KEYTRUDA Sales Grew 19% to $6.3 Billion;
June 27, 2023	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1
June 27, 2023	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1
June 27, 2023	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 1
May 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2023 (May 23, 2023) Merck UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2023 (May 23, 2023) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commis
May 22, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report Merck & Co., Inc. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report Merck & Co., Inc. (Exact Name of Registrant as Specified in Its Charter) New Jersey 1-6571 (State or other jurisdiction of incorporation or organization) (Commission File Number) 126 East Lincoln Avenue, Rahway, NJ 07065 (Address of principal executive offices) (Zip Code) Jennifer Zachary
May 22, 2023	EX-1.01	Exhibit 1.01 – Conflict Minerals Report for the reporting period January 1, 2022 to December 31, 2022. Exhibit 1.01 CONFLICT MINERALS REPORT FOR CALENDAR YEAR 2022 Part I: Introduction This document constitutes Merck & Co., Inc.’s Conflict Minerals Report (the “Report” or “CMR”) for the year ended December 31, 2022. We have prepared this Report and are issuing it in accordance with the requirements of Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and in connection with Merck & C
May 18, 2023	PX14A6G	United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Merck & Co., Inc. Name of persons relying on exemption: Boston Common Asset Management Address of p United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Merck & Co., Inc. Name of persons relying on exemption: Boston Common Asset Management Address of persons relying on exemption: 200 State Street, 7th Floor Boston, MA 02109 Written materials are submitted pursuant to Rule 14a-6(g) (1) promulgated un
May 17, 2023	EX-4.6	5.150% Notes due 2063 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2063 Notes. EX-4.6 Exhibit 4.6 5.150% NOTES DUE 2063 MERCK & CO., INC. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the Board of Directors of Merck & Co., Inc. (the “Company”) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue and sell it
May 17, 2023	EX-4.3	4.500% Notes due 2033 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2033 Notes. EX-4.3 Exhibit 4.3 4.500% NOTES DUE 2033 MERCK & CO., INC. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the Board of Directors of Merck & Co., Inc. (the “Company”) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue and sell it
May 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2023 Merck & Co., Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2023 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commission File Numb
May 17, 2023	EX-4.4	4.900% Notes due 2044 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2044 Notes. EX-4.4 Exhibit 4.4 4.900% NOTES DUE 2044 MERCK & CO., INC. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the Board of Directors of Merck & Co., Inc. (the “Company”) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue and sell it
May 17, 2023	EX-4.1	4.050% Notes due 2028 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2028 Notes. EX-4.1 Exhibit 4.1 4.050% NOTES DUE 2028 MERCK & CO., INC. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the Board of Directors of Merck & Co., Inc. (the “Company”) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue and sell it
May 17, 2023	EX-4.5	5.000% Notes due 2053 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2053 Notes. EX-4.5 Exhibit 4.5 5.000% NOTES DUE 2053 MERCK & CO., INC. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the Board of Directors of Merck & Co., Inc. (the “Company”) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue and sell it
May 17, 2023	EX-4.2	4.300% Notes due 2030 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2030 Notes. EX-4.2 Exhibit 4.2 4.300% NOTES DUE 2030 MERCK & CO., INC. Officers’ Certificate Pursuant to the resolutions (collectively, the “Resolutions”) of the Board of Directors of Merck & Co., Inc. (the “Company”) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue and sell it
May 10, 2023	424B5	$6,000,000,000 Merck & Co., Inc. $500,000,000 4.050% Notes due 2028 $750,000,000 4.300% Notes due 2030 $1,500,000,000 4.500% Notes due 2033 $750,000,000 4.900% Notes due 2044 $1,500,000,000 5.000% Notes due 2053 $1,000,000,000 5.150% Notes due 2063 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-254703 Prospectus Supplement (To Prospectus dated March 25, 2021) $6,000,000,000 Merck & Co., Inc. $500,000,000 4.050% Notes due 2028 $750,000,000 4.300% Notes due 2030 $1,500,000,000 4.500% Notes due 2033 $750,000,000 4.900% Notes due 2044 $1,500,000,000 5.000% Notes due 2053 $1,000,000,000 5.150% Notes due 2063 We are
May 10, 2023	EX-FILING FEES	Calculation of Filing Fee Table (Form Type) Merck & Co., Inc. (Exact Name of Registrant as Specified in its Charter) EX-FILING FEES 2 d358973dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) Merck & Co., Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1)
May 9, 2023	FWP	Pricing Term Sheet Merck & Co., Inc. May 8, 2023 4.050% Notes due 2028 4.300% Notes due 2030 4.500% Notes due 2033 4.900% Notes due 2044 5.000% Notes due 2053 5.150% Notes due 2063 FWP Issuer Free Writing Prospectus Filed under Rule 433 Registration Statement No.
May 8, 2023	424B5	Subject to Completion, dated May 8, 2023 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-254703 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is unlaw
May 5, 2023	10-Q	Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc. (Exact na
April 27, 2023	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 Proprietary MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2023 2022 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q Sales $ 14,487 $ 15,901 $ 14,593 $ 14,959 $ 13,830 $ 59,283 -9 % Costs, Expenses and Other Cost of sales 3,926 5,380 4,216 3,934 3,881 17,411 -27 % Selling, general and administrative 2,479 2,323 2,512
April 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2023 Merck & Co., Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2023 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-191
April 27, 2023	EX-99.1	Merck Announces First-Quarter 2023 Financial Results Exhibit 99.1 News Release Merck Announces First-Quarter 2023 Financial Results - First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines - Total Worldwide Sales Were $14.5 Billion, a Decrease of 9% From First Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth W
April 24, 2023	PX14A6G	Notice of Exempt Solicitation Notice of Exempt Solicitation Name of Registrant: Merck Name of Person Relying on Exempt Solicitation: Oxfam America Address of Person Relying on Exempt Solicitation: 77 North Washington Street, Suite 5-1, Boston, MA 02114 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934.
April 19, 2023	PX14A6G	Notice of Exempt Solicitation Notice of Exempt Solicitation Name of Registrant: Merck Name of Person Relying on Exempt Solicitation: Oxfam America Address of Person Relying on Exempt Solicitation: 77 North Washington Street, Suite 5-1, Boston, MA 02114 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934.
April 12, 2023	PX14A6G	United States Securities and Exchange Commission Washington, DC 20549 NOTICE OF EXEMPT SOLICITATION United States Securities and Exchange Commission Washington, DC 20549 NOTICE OF EXEMPT SOLICITATION NAME OF REGISTRANT: Merck & Co.
April 3, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro
April 3, 2023	DEF 14A	Schedule 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
February 24, 2023	EX-10.30	2021 CEO annual non-qualified option terms for grant under the Merck & Co., Inc. 2019 Incentive Stock Plan — Filed herewith Exhibit 10.30 TERMS FOR 2021 STOCK OPTION CEO GRANT UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: CEO Grant Exercisable Date Portion Becoming Exercisable Option Price: $73.73 May 4, 2022 First: 33.333% Grant Date: May 4, 2021 M
February 24, 2023	EX-24.2	Certified Resolution of Board of Directors Exhibit 24.2 I, Kelly Grez, Corporate Secretary of Merck & Co., Inc. (the “Company”), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 24, 2023 in accordance with the provisions of the By-Laws of the Compan
February 24, 2023	EX-10.29	2020 CEO Performance Share Unit terms for grant under the Merck & Co., Inc. 2019 Incentive Stock Plan — Filed herewith Exhibit 10.29 2020 CEO PERFORMANCE SHARE UNIT AWARD TERMS UNDER THE MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, yet-to-be-
February 24, 2023	EX-10.25	Form of stock option terms for 2020 annual non-qualified option grants under the Merck & Co., Inc. 2019 Incentive Stock Plan — Filed herewith Exhibit 10.25 TERMS FOR 2020 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: NQSO – Annual Option Price: $77.67 Grant Date: May 1, 2020 Expiration Date: April 31, 2030 Vesting Dates Portio
February 24, 2023	EX-10.28	2020 Performance Share Unit terms for grants under the Merck & Co., Inc. 2019 Incentive Stock Plan — Filed herewith Exhibit 10.28 2020 PERFORMANCE SHARE UNIT AWARD TERMS UNDER THE MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, yet-to-be-name
February 24, 2023	EX-10.35	Restricted stock unit terms for August 3, 2022 grant to Chirfi Guindo under the Merck & Co., Inc. 2019 Incentive Stock Plan - Filed herewith Exhibit 10.35 GLOBAL TERMS AND CONDITIONS 2022 RESTRICTED STOCK UNIT GRANT FOR CHIRFI GUINDO UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the Restricted Stock Unit (“RSU”) award specified in this document (“RSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country
February 24, 2023	EX-10.23	2019 terms for CEO annual non-qualified option grant under the Merck & Co., Inc. 2010 Incentive Stock Plan - Filed herewith Exhibit 10.23 TERMS FOR 2019 STOCK OPTION CEO GRANT UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: CEO Grant Exercisable Date Portion Becoming Exercisable Option Price: $77.62 May 3, 2020 First: 33.333% Grant Date: May 3, 2019 M
February 24, 2023	EX-10.8	Form of stock option terms for 2019 annual non-qualified option grants under the Merck & Co., Inc. 2010 Incentive Stock Plan - Filed herewith Exhibit 10.8 TERMS FOR 2019 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: NQSO – Annual Option Price: $77.62 Grant Date: May 3, 2019 Expiration Date: May 2, 2029 Vesting Date Portion tha
February 24, 2023	10-K	Form 10-K As filed with the Securities and Exchange Commission on February 24, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
February 24, 2023	EX-10.26	2020 terms for CEO annual non-qualified option grant under the Merck & Co., Inc. 2019 Incentive Stock Plan — Filed herewith Exhibit 10.26 TERMS FOR 2020 STOCK OPTION CEO GRANT UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: CEO Grant Exercisable Date Portion Becoming Exercisable Option Price: $75.36 May 1, 2021 First: 33.333% Grant Date: May 1, 2020 M
February 24, 2023	EX-10.33	Terms for Restricted Stock Unit Grants under the Merck & Co., Inc. 2019 Incentive Stock Plan - Filed herewith Exhibit 10.33 TERMS FOR 2021 RETENTION RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO., 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document. Different terms may apply to any prior or future RSU Awards. Grant Type: RSU Grant Date: May 4, 2021 Vesting Date Portion that Vests May 4, 2024 100% Eligibility: Eligibili
February 24, 2023	EX-21	Subsidiaries of Merck & Co., Inc. Exhibit 21 - MERCK & CO., INC. SUBSIDIARIES changes as of 12/31/2022 The following is a list of subsidiaries of the Company, doing business under the name stated. Name Country or State of Incorporation 7728026 Canada Inc. Canada Abmaxis Inc. Delaware Acceleron Pharma Inc. Delaware Afferent Pharmaceuticals, Inc. Delaware Agrident GmbH Germany Agro Verhen B.V. Netherlands Aleis Pty Ltd Australia All
February 24, 2023	EX-10.36	Performance share unit terms for August 3, 2022 grant to Chirfi Guindo under the Merck & Co., Inc. 2019 Incentive Stock Plan - Filed herewith Exhibit 10.36 GLOBAL TERMS AND CONDITIONS 2022 SIGN-ON EQUITY GRANT OF PERFORMANCE SHARE UNITS FOR CHIRFI GUINDO UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the award of Performance Share Units (“PSUs”) specified in this document (“PSU Award” or “Sign-On Equity”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, i
February 24, 2023	EX-10.27	Form of restricted stock unit terms for 2020 annual grants under the Merck & Co., Inc. 2019 Incentive Stock Plan - Filed herewith Exhibit 10.27 TERMS FOR 2020 RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO., 2019 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document. Different terms may apply to any prior or future RSU Awards. Grant Type: RSU - Annual Grant Date: May 1, 2020 Vesting Dates Portion that Vests May 1, 2021 First: 33.333% May 1, 2022
February 24, 2023	EX-10.32	2021 CEO Performance Share Unit terms for grant under the Merck & Co., Inc. 2019 Incentive Stock Plan — Filed herewith Exhibit 10.32 2021 CEO PERFORMANCE SHARE UNIT AWARD TERMS UNDER THE MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, independen
February 24, 2023	EX-10.24	Form of restricted stock unit terms for 2019 annual grants under the Merck & Co., Inc. 2010 Incentive Stock Plan - Filed herewith Exhibit 10.24 TERMS FOR 2019 RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document. Different terms may apply to any prior or future RSU Awards. Grant Type: RSU Grant Date: May 3, 2019 Vesting Date Portion that Vests May 3, 2020 First: 33.333% May 3, 2021 Secon
February 24, 2023	EX-24.1	Power of Attorney Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned does hereby appoint JENNIFER ZACHARY as his/her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2022 under th
February 24, 2023	EX-10.7	Form of stock option terms for 2017 annual non-qualified option grants under the Merck & Co., Inc. 2010 Incentive Stock Plan - Filed herewith Exhibit 10.7 TERMS FOR 2017 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option. Grant Type: NQSO Option Price: $63.97 Grant Date: May 5, 2017 Expiration Date: May 4, 2027 Vesting Date Portion that Vests M
February 24, 2023	EX-10.37	Offer Letter between Merck & Co., Inc. and Chirfi Guindo, dated June 8, 2022 - Filed herewith Exhibit 10.37 June 8, 2022 Chirfi Guindo Dear Chirfi, It is my pleasure to offer you a position with Merck Sharp & Dohme LLC (“MSD” or the “Company”), a wholly-owned subsidiary of Merck & Co., Inc. (“Merck”), as its Chief Marketing Officer (the “Position”) on the terms and conditions set forth in this offer letter (“letter” or “offer letter”). We see ourselves as a company inspired to invent, and
February 24, 2023	EX-10.13	Merck & Co., Inc. U.S. Separation Benefits Plan (amended and restated as of January 1, 2019) as further amended by Amendments 2019-1 (as of December 19, 2019), 2020-1 (as of February 25, 2020), 2020-2 (as of December 10, 2020), 2021-1 (as of March 31, 2021), 2021-2 (as of December 16, 2021), 2022-1 (as of December 14, 2022) and 2022-2 (as of December 13, 2021) - Filed herewith Exhibit 10.13 MERCK & CO. INC. U.S. SEPARATION BENEFITS PLAN Amended and Restated as of January 1, 2019 MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN SECTION 1 PREAMBLE Merck Sharp & Dohme Corp. established the MSD Separation Benefits Plan (the "MSD Plan"), as amended from time to time, to provide benefits to eligible non-union employees whose employment with Merck Sharp & Dohme Corp. or a part
February 24, 2023	EX-10.31	2021 Performance Share Unit terms for grants under the Merck & Co., Inc. 2019 Incentive Stock Plan — Filed herewith Exhibit 10.31 2021 PERFORMANCE SHARE UNIT AWARD TERMS UNDER THE MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, independent, p
February 24, 2023	EX-10.34	Restricted stock unit terms for May 3, 2022 and August 3, 2022 grants to Executive Chairman under the Merck & Co., Inc. 2019 Incentive Stock Plan — Filed herewith Exhibit 10.34 TERMS AND CONDITIONS 2022 EXECUTIVE CHAIRMAN RESTRICTED STOCK UNIT GRANT UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the Restricted Stock Unit (“RSU”) award specified in this document (“RSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan (the “Plan”). This RSU Award is subject to the terms a
February 9, 2023	SC 13G/A	MRK / Merck & Co., Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0082-merckcoinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Merck & Co. Inc. Title of Class of Securities: Common Stock CUSIP Number: 58933Y105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rul
February 2, 2023	EX-99.1	Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results - Fourth-Quarter and Full-Year 2022 Results Reflect Sustained Strong Revenue Growth - Fourth-Quarter 2022 Worldwide Sales Were $13.8 Billion, an Increase of 2% From Fourth Quarter 2021; Growth Excluding the Impact of Foreign Exchange Was 8% - Fourth-Quarter 2022 GAAP EPS From Continu
February 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2023 Merck & Co., Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2023 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1
February 2, 2023	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2022 2021 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year Sales $ 15,901 $ 14,593 $ 14,959 $ 13,830 $ 59,283 $ 10,627 $ 11,402 $ 13,154 $ 13,521 $ 48,704 2 % 22 % Costs, Expenses and Other Cost of sales 5,380 4,216 3,934 3,881 17,411 3,199 3,
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co.,
October 27, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2022 (October 26, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2022 (October 26, 2022) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commissio
October 27, 2022	EX-99.3	Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck Frazier to Retire After 30 years at Merck; Board of Directors Elects Davis as Company Chairman Exhibit 99.3 News Release Media Contact: Johanna Herrmann Investor Contact: Peter Dannenbaum (617) 216-6029 (908) 740-1037 Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck Frazier to Retire After 30 years at Merck; Board of Directors Elects Davis as Company Chairman RAHWAY, N.J., October 26, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announ
October 27, 2022	EX-99.1	Merck Announces Third-Quarter 2022 Financial Results Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Merck Announces Third-Quarter 2022 Financial Results · Third-Quarter Results Reflect Sustained Strong Business Momentum Across Key Growth Drivers as Well as Investment and Progress in the Pipeline · Third-Quarter 2022 Worldwide Sales Were $15.0 Billion, an Increase of 14% From Third-Quarter 2021; LAGEVRIO Sales Were $436 Million; Growth Excluding LAG
October 27, 2022	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2022 2021 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD Sales $ 15,901 $ 14,593 $ 14,959 $ 45,453 $ 10,627 $ 11,402 $ 13,154 $ 35,183 $ 13,521 $ 48,704 14 % 29 % Costs, Expenses and Other Cost of sales 5,380 4,216 3,934 13,530 3,199 3,104
August 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc.
July 28, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 28, 2022 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1918
July 28, 2022	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2022 2021 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD Sales $ 15,901 $ 14,593 $ 30,494 $ 10,627 $ 11,402 $ 22,029 $ 13,154 $ 13,521 $ 48,704 28 % 38 % Costs, Expenses and Other Cost of sales 5,380 4,216 9,596 3,199 3,104 6,303 3,450 3,87
July 28, 2022	EX-99.1	Merck Announces Second-Quarter 2022 Financial Results Exhibit 99.1 News Release Merck Announces Second-Quarter 2022 Financial Results - Merck Delivers Robust Sales Growth and Important Clinical Advancements in Second Quarter - Second-Quarter 2022 Worldwide Sales Were $14.6 Billion, an Increase of 28% From Second Quarter 2021; LAGEVRIO Sales Were $1.2 Billion, Growth Excluding LAGEVRIO Was 18%; Growth Excluding LAGEVRIO and the Impact From Foreign Exc
June 15, 2022	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 1
June 15, 2022	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 11-K 1 a11-kmsdemployeestockpurc.htm FORM 11-K: MSD EMPLOYEE STOCK PURCHASE AND SAVINGS PLAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF
June 15, 2022	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 1
May 26, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2022 (May 24, 2022) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction (Commission (I.R.S Employ
May 20, 2022	EX-1.01	Exhibit 1.01 – Conflict Minerals Report for the reporting period January 1, 2021 to December 31, 2021. Exhibit 1.01 CONFLICT MINERALS REPORT FOR CALENDAR YEAR 2021 Part I: Introduction This document constitutes Merck & Co., Inc.?s Conflict Minerals Report (the ?Report? or ?CMR?) for the year ended December 31, 2021. We have prepared this Report and are issuing it in accordance with the requirements of Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and in connection with Merck & C
May 20, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report Merck & Co., Inc. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report Merck & Co., Inc. (Exact Name of Registrant as Specified in Its Charter) New Jersey 1-6571 (State or other jurisdiction of incorporation or organization) (Commission File Number) 126 East Lincoln Avenue, Rahway, NJ 07065 (Address of principal executive offices) (Zip Code) Jennifer Zachary
May 13, 2022	PX14A6G	Notice of Exempt Solicitation Notice of Exempt Solicitation NAME OF REGISTRANT: Merck NAME OF PERSON RELYING ON EXEMPTION: Oxfam America ADDRESS OF PERSON RELYING ON EXEMPTION: 226 Causeway Street, Boston, MA 02114 Written materials are submitted pursuant to Rule 14(a)-6(g)(1) promulgated under the Securities and Exchange Act of 1934.
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc
April 28, 2022	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2022 2021 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q Sales $ 15,901 $ 10,627 $ 11,402 $ 13,154 $ 13,521 $ 48,704 50 % Costs, Expenses and Other Cost of sales 5,380 3,199 3,104 3,450 3,873 13,626 68 % Selling, general and administrative 2,323 2,187 2,281 2,336 2,830
April 28, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 28, 2022 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-191
April 28, 2022	EX-99.1	Merck Announces First-Quarter 2022 Financial Results Exhibit 99.1 News Release Media Contacts: Melissa Moody Investor Contacts: Peter Dannenbaum (215) 407-3536 (908) 740-1037 Johanna Herrmann (617) 216-6029 Steven Graziano (908) 740-6582 Merck Announces First-Quarter 2022 Financial Results - First-Quarter 2022 Results Reflect Sustained Strong Business Momentum, With Robust Top- and Bottom-Line Growth - First-Quarter 2022 Worldwide Sales From Continu
April 21, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 20, 2022 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-191
April 21, 2022	EX-99.1	2021 and 2020 Historical Non-GAAP Financial Information Recast to Reflect Reporting Changes Exhibit 99.1 MERCK & CO., INC. 2021 QUARTERLY AND ANNUAL GAAP TO NON-GAAP RECONCILIATIONS - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) In 2022, the Company will be changing the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck?s non-GAAP results excluded expenses for upfront and milestone payments related to collaborations
April 4, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 d154286ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as
April 4, 2022	DEF 14A	DEF 14A
April 4, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
March 25, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 25, 2022 (March 22, 2022) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction (Commission (I.R.S Em
March 25, 2022	EX-3.1	By-Laws of Merck & Co., Inc. (effective March 22, 2022) – Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571) Exhibit 3.1 By-Laws OF MERCK & CO., INC. Effective as of March 22, 2022 By-Laws OF Merck & Co., Inc. A R T I C L E I. SHAREHOLDERS. SECTION 1. Annual Meeting. A meeting of the shareholders of Merck & Co., Inc. (hereinafter referred to as the ?Company?) shall be held at such places as may from time to time be designated by the Board of Directors and stated in the notice of the meeting for the purpo
February 25, 2022	EX-21	Subsidiaries of Merck & Co., Inc. EXHIBIT 21 MERCK & CO., INC. SUBSIDIARIES as of 12/31/2021 The following is a list of subsidiaries of the Company, doing business under the name stated. Name Country or State of Incorporation 7728026 Canada Inc. Canada Abmaxis Inc. Delaware Acceleron Holding Ltd. Bermuda Acceleron Pharma Canada Inc. Canada (BC) Acceleron Pharma Germany GmbH Germany Acceleron Pharma Inc. Delaware Acceleron Pharma N
February 25, 2022	EX-10.25	Form of restricted stock unit terms for 2022 annual grants under the Merck & Co., Inc. 2019 Incentive Stock Plan Exhibit 10.25 GLOBAL TERMS AND CONDITIONS 2022 RESTRICTED STOCK UNIT GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN Grant Type: RSU - Annual Grant Date: May 3, 2022 Vesting Dates Portion that Vests May 3, 2023 First: 33.333% May 3, 2024 Second: 33.333% May 3, 2025 Third: Balance I.GENERAL. Merck & Co., Inc. (the ?Company?) has granted to you the Restricted Stock Unit (?RSU?) award sp
February 25, 2022	EX-10.24	Form of stock option terms for 2022 annual non-qualified option grants under the Merck & Co., Inc. 2019 Incentive Stock Plan Exhibit 10.24 GLOBAL TERMS AND CONDITIONS 2022 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN Grant Type: NQSO ? Annual Option Price: $XX.XX Grant Date: May 3, 2022 Expiration Date: May 2, 2032 Vesting Dates Portion that Vests May 3, 2023 First: 33.333% May 3, 2024 Second: 33.333% May 3, 2025 Third: Balance I.GENERAL Merck & Co., Inc. (the ?Company?)
February 25, 2022	EX-10.17	Merck & Co., Inc. Plan for Deferred Payment of Directors’ Compensation (Amended and Restated effective as of January 1, Exhibit 10.17 MERCK & CO., INC. PLAN FOR DEFERRED PAYMENT OF DIRECTORS' COMPENSATION (Effective as Amended and Restated January 1, 2022) TABLE OF CONTENTS Page Article I Purpose 1 Article II Election of Deferral, Investment Alternatives and Distribution Schedule 1 Article III Valuation of Deferred Amounts 3 Article IV Redesignation Within a Deferral Account 5 Article V Payment of Deferred Amounts
February 25, 2022	10-K	As filed with the Securities and Exchange Commission on February 25, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K As filed with the Securities and Exchange Commission on February 25, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
February 25, 2022	EX-24.2	Certified Resolution of Board of Directors Exhibit 24.2 I, Kelly Grez, Deputy Corporate Secretary of Merck & Co., Inc. (the ?Company?), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 25, 2022 in accordance with the provisions of the By-Laws of the
February 25, 2022	EX-24.1	Power of Attorney Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned does hereby appoint JENNIFER ZACHARY as his/her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2021 under th
February 9, 2022	SC 13G/A	MRK / Merck & Co., Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0070-merckcoinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Merck & Co. Inc. Title of Class of Securities: Common Stock CUSIP Number: 58933Y105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rul
February 3, 2022	EX-99.1	Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results Exhibit 99.1 News Release Media Contacts: Melissa Moody (215) 407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Johanna Herrmann (617) 216-6029 Steven Graziano (908) 740-6582 Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results ? Fourth-Quarter and Full-Year Results Reflect Continued Strong Business Momentum and Operational Strength ? Fourth-Quarter 2021 Worldwide Sales Fr
February 3, 2022	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2021 2020 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year Sales $ 10,627 $ 11,402 $ 13,154 $ 13,521 $ 48,704 $ 10,288 $ 9,353 $ 10,929 $ 10,948 $ 41,518 24 % 17 % Costs, Expenses and Other Cost of sales 3,199 3,104 3,450 3,873 13,626 2,829 2,
February 3, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 3, 2022 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1
February 2, 2022	SC 13G	LBPS / 4D pharma plc / Merck & Co., Inc. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 4D pharma plc Ordinary Shares, nominal value ?0.0025 per share (Title of Class of Securities) 35085K109** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
February 2, 2022	EX-99.1	Joint Filing Agreement Pursuant to Rule 13d-1 EXHIBIT 99.1 Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the ?Act?) by and among the parties listed below, each referenced to herein as a ?Joint Filer.? The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereu
December 10, 2021	EX-4.1	1.700% Notes due 2027 Officers’ Certificate of the Company dated December 10, 2021, including form of the 2027 Notes. Exhibit 4.1 EXECUTION VERSION 1.700% NOTES DUE 2027 MERCK & CO., INC. Officers? Certificate Pursuant to the resolutions (collectively, the ?Resolutions?) of the Board of Directors of Merck & Co., Inc. (the ?Company?) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue
December 10, 2021	EX-4.5	2.900% Notes due 2061 Officers’ Certificate of the Company dated December 10, 2021, including form of the 2061 Notes. Exhibit 4.5 EXECUTION VERSION 2.900% NOTES DUE 2061 MERCK & CO., INC. Officers? Certificate Pursuant to the resolutions (collectively, the ?Resolutions?) of the Board of Directors of Merck & Co., Inc. (the ?Company?) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue
December 10, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2021 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commission File
December 10, 2021	EX-4.2	1.900% Notes due 2028 Officers’ Certificate of the Company dated December 10, 2021, including form of the 2028 Notes. Exhibit 4.2 EXECUTION VERSION 1.900% NOTES DUE 2028 MERCK & CO., INC. Officers? Certificate Pursuant to the resolutions (collectively, the ?Resolutions?) of the Board of Directors of Merck & Co., Inc. (the ?Company?) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue
December 10, 2021	EX-4.4	2.750% Notes due 2051 Officers’ Certificate of the Company dated December 10, 2021, including form of the 2051 Notes. Exhibit 4.4 EXECUTION VERSION 2.750% NOTES DUE 2051 MERCK & CO., INC. Officers? Certificate Pursuant to the resolutions (collectively, the ?Resolutions?) of the Board of Directors of Merck & Co., Inc. (the ?Company?) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue
December 10, 2021	EX-4.3	2.150% Notes due 2031 Officers’ Certificate of the Company dated December 10, 2021, including form of the 2031 Notes. Exhibit 4.3 EXECUTION VERSION 2.150% NOTES DUE 2031 MERCK & CO., INC. Officers? Certificate Pursuant to the resolutions (collectively, the ?Resolutions?) of the Board of Directors of Merck & Co., Inc. (the ?Company?) adopted at meetings duly called and held on March 23, 2021 and November 30, 2021 (at which meetings a quorum was present and acting throughout), which authorized the Company to issue
December 9, 2021	424B5	CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per security Maximum aggregate offering price Amount of registration fee (1) 1.700% Notes due 2027 $1,500,000,000 99.958 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254703 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered Maximum offering price per security Maximum aggregate offering price Amount of registration fee (1) 1.700% Notes due 2027 $1,500,000,000 99.958% $1,499,370,000 $138,991.60 1.900% Notes due 2028 $1,000,000,000 99.82
December 8, 2021	FWP	Pricing Term Sheet Merck & Co., Inc. December 7, 2021 1.700% Notes due 2027 1.900% Notes due 2028 2.150% Notes due 2031 2.750% Notes due 2051 2.900% Notes due 2061 FWP 1 d253432dfwp.htm FWP Issuer Free Writing Prospectus Filed under Rule 433 Registration Statement No. 333-254703 Pricing Term Sheet Merck & Co., Inc. December 7, 2021 1.700% Notes due 2027 1.900% Notes due 2028 2.150% Notes due 2031 2.750% Notes due 2051 2.900% Notes due 2061 Unless otherwise indicated, terms used but not defined herein have the meanings assigned to such terms in the preliminar
December 7, 2021	424B5	Subject to Completion, dated December 7, 2021 424B5 1 d128376d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-254703 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where
November 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co.,
October 28, 2021	EX-99.1	Merck Announces Third-Quarter 2021 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contacts: Patrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Melissa Moody Raychel Kruper (215) 407-3536 (908) 740-2107 Merck Announces Third-Quarter 2021 Financial Results ? Results Demonstrate Strong Momentum Across Business ? Third-Quarter 2021 Worldwide Sales Were $13.2 Billion, 20% Above Third-Quarter 2020; Excluding the Imp
October 28, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 28, 2021 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1
October 28, 2021	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2021 2020 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD Sales $ 10,627 $ 11,402 $ 13,154 $ 35,183 $ 10,288 $ 9,353 $ 10,929 $ 30,570 $ 10,948 $ 41,518 20% 15% Costs, Expenses and Other Cost of sales 3,199 3,104 3,450 9,752 2,829 2,747 3,01
October 15, 2021	EX-99.25	EX-99.25 EX-99.25 2 ruleprovisionnotice.htm NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on October 26, 2021, pursuant to the provisions of Rule 12d2-2 (a). [ X ] 17 CFR 240.12d
August 20, 2021	EX-99.1	Leslie A. Brun Resigns from Merck Board of Directors Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Media Contacts: Patrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Melissa Moody (215) 407-3536 Raychel Kruper (908) 740-2107 Leslie A. Brun Resigns from Merck Board of Directors KENILWORTH, N.J., Aug. 20, 2021 ? Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Leslie A. Brun, its
August 20, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 20, 2021 (August 19, 2021) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (
August 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-6571 Merck & Co., Inc.
July 29, 2021	EX-99.2	MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Table 1a Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2021 2020 % Change 1Q 2Q June YTD 1Q 2Q June YTD 3Q 4Q Full Year 2Q June YTD Sales $ 10,627 $ 11,402 $ 22,029 $ 10,288 $ 9,353 $ 19,641 $ 10,929 $ 10,948 $ 41,518 22 % 12 % Costs, Expenses and Other Cost of sales 3,199 3,104 6,303 2,829 2,747 5,576 3,013 5,029
July 29, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2021 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1918
July 29, 2021	EX-99.1	Merck Announces Second-Quarter 2021 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contacts: Patrick Ryan Investor Contacts: Peter Dannenbaum (973) 275-7075 (908) 740-1037 Melissa Moody (215) 407-3536 Raychel Kruper (908) 740-2107 Merck Announces Second-Quarter 2021 Financial Results ? Second-Quarter 2021 Worldwide Sales from Continuing Operations (Excluding Organon) Were $11.4 Billion, 22% Above Second-Quarter 2020; Excluding the Impact
June 21, 2021	EX-99.1	MERCK & CO., INC. FIRST QUARTER 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Exhibit 99.1 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) On June 2, 2021, Merck completed the spinoff of products from its women?s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon?s publicly traded stock to c
June 21, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 21, 2021 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey (State or other jurisdiction of incorporation) 1-6571 (Commission File Number) 22-1918
June 16, 2021	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 11-K 1 a11-kmerckussavingsplanye.htm FORM 11-K: MERCK US SAVINGS PLAN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal yea
June 16, 2021	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 1
June 16, 2021	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS Pursuant to Section 15(d) of the Securities Exchange Act of 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 1
June 3, 2021	8-K	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2021 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commission File Numb
May 27, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2021 (May 25, 2021) Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction (Commission (I.R.S Employ

SGP / Schering Plough Corp - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)